Reported 13 days ago
Shares of Novo Nordisk and Eli Lilly fell sharply after former President Trump suggested that the price of Ozempic, a popular diabetes and weight-loss drug, might reduce to $150 per month, down from its current list price of around $1,000. This potential price cut, which Trump announced during a press conference, raised concerns about the companies' market position amidst ongoing negotiations for drug pricing. Analysts note that most patients already pay significantly less than the published list prices due to insurance rebates, indicating that Trump's claims may not radically alter the dynamics for Novo and Lilly.
Source: YAHOO